scholarly article | Q13442814 |
P50 | author | Joseph Bresee | Q61189679 |
Daniel Jernigan | Q85342211 | ||
Alicia M Fry | Q87077992 | ||
P2093 | author name string | Emmanuel B Walter | |
Leslie Z Sokolow | |||
Karen R Broder | |||
Lisa A Grohskopf | |||
P2860 | cites work | Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13. | Q30202827 |
Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States | Q30388312 | ||
High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season | Q30425045 | ||
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010 | Q34129986 | ||
Efficacy of high-dose versus standard-dose influenza vaccine in older adults | Q34433416 | ||
Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age. | Q36009663 | ||
Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults | Q36154661 | ||
Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy | Q36201827 | ||
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination | Q36306922 | ||
Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons | Q36964157 | ||
Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? | Q37084793 | ||
Recommendations for the administration of influenza vaccine in children allergic to egg. | Q37597769 | ||
Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. | Q38403538 | ||
Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season | Q38420094 | ||
Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. | Q38438083 | ||
Influenza virus infection in travelers to tropical and subtropical countries. | Q39284878 | ||
Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial | Q40073913 | ||
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older | Q40151067 | ||
Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months | Q40318118 | ||
The underrecognized burden of influenza in young children. | Q40475111 | ||
Prevention and Control of Seasonal Influenza with Vaccines | Q40607746 | ||
Cruise ships: high-risk passengers and the global spread of new influenza viruses | Q40615126 | ||
Febrile Seizure Risk After Vaccination in Children 6 to 23 Months | Q40713270 | ||
Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months | Q40845505 | ||
Trials of Influenza A/New Jersey/76 Virus Vaccine in Normal Children: An Overview of Age-Related Antigenicity and Reactogenicity | Q40879321 | ||
Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants | Q40892205 | ||
Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time | Q40931032 | ||
Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults | Q40933588 | ||
Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines | Q41089501 | ||
From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--I | Q41516459 | ||
Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty | Q41574817 | ||
Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons | Q42081471 | ||
Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia | Q42276385 | ||
Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence | Q43174206 | ||
A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children | Q43174883 | ||
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years | Q44955827 | ||
Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary | Q45056829 | ||
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study | Q47852548 | ||
Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: reactogenicity, immunogenicity and persistence of antibodies following two doses of vaccines. | Q50576656 | ||
Large Summertime Influenza A Outbreak among Tourists in Alaska and the Yukon Territory | Q51676032 | ||
Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. | Q54272482 | ||
Influenza- and RSV-associated hospitalizations among adults | Q57384999 | ||
Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine‐Naive 5–8‐Year‐Old Children | Q57385003 | ||
Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection | Q57385728 | ||
Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in a | Q57793454 | ||
Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study | Q59617109 | ||
Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP) | Q64131126 | ||
Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78 | Q69536044 | ||
Impact of epidemic type A influenza in a defined adult population | Q71461858 | ||
Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season | Q79396301 | ||
Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age | Q80797079 | ||
Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older | Q81379333 | ||
Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses | Q81920819 | ||
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children | Q82214819 | ||
Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP) | Q82636961 | ||
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host | Q87092630 | ||
The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly | Q87232318 | ||
P433 | issue | 2 | |
P921 | main subject | immunization | Q1415366 |
P304 | page(s) | 1-20 | |
P577 | publication date | 2017-08-25 | |
P1433 | published in | Morbidity and Mortality Weekly Report: Recommendations and Reports | Q23930023 |
P1476 | title | Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season | |
P478 | volume | 66 |
Q47680688 | A multi-site feasibility study to assess fever and wheezing in children after influenza vaccines using text messaging. |
Q92668947 | A paediatric influenza update 100 years after the Skyros island Spanish flu outbreak |
Q64898397 | A population-based study of maternal and infant factors influencing influenza vaccination among young children born in Colorado from 2008 to 2016. |
Q98186520 | A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season |
Q92456759 | A review of the cost-effectiveness of adult influenza vaccination and other preventive services |
Q91652613 | A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of age |
Q88983080 | Actividades preventivas en la mujer. Actualización PAPPS 2018 |
Q50115044 | Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2018. |
Q91614864 | Alternative-Dose versus Standard-Dose Trivalent Influenza Vaccines for Immunocompromised Patients: A Meta-Analysis of Randomised Control Trials |
Q57469672 | An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States |
Q63247049 | Announcement: National Birth Defects Prevention Month and Folic Acid Awareness Week - January 2018 |
Q59353186 | Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance |
Q90209648 | Are children with special risk medical conditions receiving influenza vaccination? Validity of parental and provider report, and to a National Immunisation Register |
Q64135849 | Association between patient reminders and influenza vaccination status among children |
Q64137752 | Association between provider recommendation and influenza vaccination status among children |
Q57178948 | Beliefs, attitudes, and barriers associated with the uptake of the seasonal influenza vaccine among patients visiting primary healthcare clinics |
Q89965369 | Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics |
Q64245361 | Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations |
Q61816519 | Can online self-reports assist in real-time identification of influenza vaccination uptake? A cross-sectional study of influenza vaccine-related tweets in the USA, 2013-2017 |
Q64054477 | Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: possible cohort effect following the 2009 influenza pandemic |
Q91991655 | Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women |
Q94672299 | Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season |
Q91647242 | Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis |
Q92993339 | Cost effectiveness of school-located influenza vaccination programs for elementary and secondary school children |
Q55716746 | Demographics, perceptions, and socioeconomic factors affecting influenza vaccination among adults in the United States. |
Q92893309 | Determinants of Seasonal Influenza Vaccine Uptake Among the Elderly in the United States: A Systematic Review and Meta-Analysis |
Q90314555 | Determinants of healthcare workers' willingness to recommend the seasonal influenza vaccine to diabetic patients: A cross-sectional survey in Ningbo, China |
Q49926306 | Development and pilot testing of a text message vaccine reminder system for use during an influenza pandemic. |
Q52589345 | Direct-to-adolescent text messaging for vaccine reminders: What will parents permit? |
Q57814655 | Do parents prefer inactivated or live attenuated influenza vaccine for their children? |
Q92499108 | Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis |
Q64133134 | Effectiveness of trivalent inactivated influenza vaccine among community-dwelling older adults in Thailand: A two-year prospective cohort study |
Q64130978 | Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season |
Q91238196 | Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles |
Q92437525 | Evaluation of A(H1N1)pdm09 LAIV vaccine candidates stability and replication efficiency in primary human nasal epithelial cells |
Q59351771 | Evaluation of the field-protective effectiveness of seasonal influenza vaccine among Korean children aged < 5 years during the 2014-2015 and 2015-2016 influenza seasons: a cohort study |
Q89881323 | Factors associated with referring close contacts to an app with individually-tailored vaccine information |
Q90344692 | Frequency and cost of live vaccines administered too soon after prior live vaccine in children aged 12 months through 6 years, 2014-2017 |
Q91774677 | Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study |
Q89125909 | High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial |
Q90419091 | Host Single Nucleotide Polymorphisms Modulating Influenza A Virus Disease in Humans |
Q88310213 | How do we best prevent influenza in young children? |
Q47169865 | Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization. |
Q90597820 | Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study |
Q43365954 | Impact of Human Immunodeficiency Virus on the Burden and Severity of Influenza Illness in Malawian Adults: A Prospective Cohort and Parallel Case-Control Study |
Q50101280 | Impact of aging and HIV infection on serologic response to seasonal influenza vaccination |
Q90128042 | Impact of funding influenza vaccination on coverage among Australian children: a national study using MedicineInsight, a large general practice database |
Q91789123 | Improving Influenza Vaccination Coverage Among Patients With COPD: A Pilot Project |
Q90858175 | Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season |
Q64374818 | Incidence and seasonality of respiratory viruses causing acute respiratory infections in the Northern United Arab Emirates |
Q90241630 | Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis |
Q92763525 | Infections Caused by Influenza Viruses Among Children in Poland During the 2017/18 Epidemic Season |
Q95363302 | Inflammatory Mediator Expression Associated With Antibody Response Induced by Live Attenuated vs Inactivated Influenza Virus Vaccine in Children |
Q64123985 | Influenza |
Q56985884 | Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance |
Q47560061 | Influenza B virus infection and Stevens-Johnson syndrome. |
Q58563490 | Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications |
Q91971734 | Influenza and Antibody-Dependent Cellular Cytotoxicity |
Q58796174 | Influenza and Tdap Vaccination Coverage Among Pregnant Women - United States, April 2018 |
Q64135846 | Influenza vaccination among adults living with persons at high-risk for complications from influenza during early 2016–17 influenza season |
Q93219467 | Influenza vaccination: Uptake and associations in a cross-sectional study of children with special risk medical conditions |
Q90538926 | Influenza vaccine coverage, awareness, and beliefs regarding seasonal influenza vaccination among people aged 65 years and older in Central Saudi Arabia |
Q64129863 | Influenza-Related Communication and Community Mitigation Strategies: Results From the 2015 Pandemic Influenza Readiness Assessment |
Q49829189 | Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens |
Q38957414 | Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017. |
Q49981002 | Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. |
Q54232174 | Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses. |
Q87874410 | Intranasal influenza vaccine: Why does Canada have different recommendations from the USA on its use? |
Q49974968 | Is Dr von Magnus to blame for the withdrawal of live attenuated influenza vaccine? |
Q94423521 | Les recommandations relatives aux vaccins antigrippaux administrés aux enfants et aux adolescents pour la saison 2017-2018 |
Q93375313 | Licensing the first reduced, 6 µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine - A randomized-controlled multicenter trial |
Q64137087 | Low coverage rate and awareness of influenza vaccine among older people in Shanghai, China: A cross-sectional study |
Q58122560 | Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice |
Q92762684 | Modification of the vaccine manufacturing process improves the pyrogenicity profile of inactivated influenza vaccines in young children |
Q60959439 | Modulation of Innate Immune Responses by the Influenza A NS1 and PA-X Proteins |
Q64116962 | Novel Approaches for The Development of Live Attenuated Influenza Vaccines |
Q52599675 | Novel Platforms for the Development of a Universal Influenza Vaccine. |
Q92711478 | Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis |
Q59349088 | Optimizing the impact of low-efficacy influenza vaccines |
Q58584065 | Paid sick leave benefits, influenza vaccination, and taking sick days due to influenza-like illness among U.S. workers |
Q41930762 | Perspectives from the society for pediatric research (SPR): Decreased effectiveness of the live attenuated influenza vaccine (LAIV). |
Q92374807 | Prevalence and associated factors of influenza vaccination coverage in Korean adults with cardiovascular disease |
Q92110843 | Prevalence of influenza and pneumococcal vaccine uptake in Saudi type 2 diabetic individuals |
Q58709341 | Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season |
Q64134459 | Prevention of influenza hospitalization among adults in the US, 2015-16: Results from the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) |
Q53076429 | Preventive behaviors adults report using to avoid catching or spreading influenza, United States, 2015-16 influenza season. |
Q90339280 | Prior vaccinations improve immunogenicity of inactivated influenza vaccine in young children aged 6 months to 3 years: A cohort study |
Q87989165 | Probing Beyond Individual Factors to Understand Influenza and Pneumococcal Vaccine Uptake |
Q92716364 | Racial disparities in U.S. maternal influenza vaccine uptake: Results from analysis of Pregnancy Risk Assessment Monitoring System (PRAMS) data, 2012-2015 |
Q57292231 | Racial/Ethnic Disparities in Influenza Vaccination Coverage Among US Adolescents, 2010-2016 |
Q57182362 | Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women |
Q57093943 | Readiness for Responding to a Severe Pandemic 100 Years After 1918 |
Q101163380 | Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies |
Q94587505 | Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness |
Q92760509 | SIMON, an Automated Machine Learning System, Reveals Immune Signatures of Influenza Vaccine Responses |
Q58617792 | Safety and Immunogenicity of a Full-Dose Split-Virion Inactivated Quadrivalent Influenza Vaccine in Healthy Children 6 to 35 Months of Age: A Randomized Controlled Clinical Trial |
Q57093614 | Seasonal Influenza Vaccine Impact on Pandemic H1N1 Vaccine Efficacy |
Q64076721 | Seasonal influenza: Knowledge, attitude and vaccine uptake among adults with chronic conditions in Italy |
Q93016369 | Should rare immunologic, neurologic, and other adverse events be indications to withhold vaccination? |
Q57466491 | Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine |
Q89867698 | Tetanus, Diphtheria, and Acellular Pertussis and Influenza Vaccinations among Women With a Live Birth, Internet Panel Survey, 2017-2018 |
Q57166818 | The Future of Influenza Vaccines: A Historical and Clinical Perspective |
Q46144181 | The challenge of vaccine policy-making with imperfect data. |
Q90267717 | Transgender and Nontrans Patients Do Not Receive Statistically Different Quality Primary Care at Whitman-Walker Health, 2008-2016 |
Q58120075 | Understanding the unique characteristics of seasonal influenza illness to improve vaccine uptake in the US |
Q54981943 | Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. |
Q41923696 | Update: Influenza Activity - United States and Worldwide, May 21-September 23, 2017. |
Q47350852 | Update: Influenza Activity - United States, October 1-November 25, 2017. |
Q92604918 | Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes |
Q47595817 | Vaccination choices for older people, looking beyond age specific approaches |
Q90036155 | Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient |
Q50208587 | Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season |
Q89526678 | Vaccine hesitancy and influenza beliefs among parents of children requiring a second dose of influenza vaccine in a season: An American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) study |
Q51409632 | Vaccine recommendations for children and youth for the 2017/2018 influenza season. |
Q50056475 | Vaccine-associated hypersensitivity. |
Q59352281 | Viral etiological causes of febrile seizures for respiratory pathogens (EFES Study) |
Q91146451 | Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States |
Q38690527 | Workplace interventions associated with influenza vaccination coverage among health care personnel in ambulatory care settings during the 2013-2014 and 2014-2015 influenza seasons |
Q56765738 | Zoonotic Influenza and Human Health—Part 2: Clinical Features, Diagnosis, Treatment, and Prevention Strategies |
Q59351197 | [Description of Influenza B in seasonal epidemics in Spain] |
Q93344976 | [The universal influenza vaccination in children with Vaxigrip Tetra® in Italy: an evaluation of Health Technology Assessment] |
Search more.